By Dominic Chopping

STOCKHOLM--EQT will acquire a majority stake in CluePoints, a cloud-based, AI-powered software platform used to identify and mitigate data quality risks in clinical trials.

"As scientific breakthroughs and advancements in technology and data are accelerating healthcare innovation, the markets for risk-based quality management and data interrogation & analytics software are expected to experience strong growth," the Swedish private-equity firm said Wednesday.

Founded in 2012 and headquartered in Belgium, CluePoints identifies initial risks and provides tracking and monitoring of issues and discrepancies throughout the drug development process. It has over 9,500 platform users.

Summit Partners, an investor in CluePoints since 2020, and co-founder Clinimetrics will both retain minority stakes.

Financial terms weren't disclosed.

The deal is expected to close in the third quarter of 2024, subject to conditions.

Write to Dominic Chopping at

(END) Dow Jones Newswires

06-12-24 0446ET